Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 7,591 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bones Clear all
Withdrawn No phase listed Observational

Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia

NCT07607600
View directory record Official record
Conditions
X-linked Hypophosphatemia (XLH)
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Impact of Targeted Therapy on Cancer-Related Cognitive Impairment

NCT07638007
View directory record Official record
Conditions
Disease/Condition Name Cancer-related Cognitive Dysfunction, Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
Not listed
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Completed Not applicable Interventional

Telerehabilitation Following Ankle Fractures

NCT04235907
View directory record Official record
Conditions
Ankle Fractures
Interventions
Telerehabilitation, Standard rehabilitation
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 31, 2026, 2:02 PM EDT
Completed Phase 2 Interventional

STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis

NCT00006475
View directory record Official record
Conditions
Leukemia
Interventions
imatinib mesylate
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 31, 2026, 2:02 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Program of Ponatinib

NCT01592136
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Interventions
ponatinib
Drug
Lead sponsor
Ariad Pharmaceuticals
Industry
Eligibility
18 Years and older
U.S. locations
33
States / cities
La Jolla, California • San Marcos, California • Vallejo, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 31, 2026, 2:02 PM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

NCT04370301
View directory record Official record
Conditions
Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Cyclophosphamide, JAK Inhibitor, Fludarabine, Recombinant Granulocyte Colony-Stimulating Factor, Melphalan, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Computed Tomography, Magnetic Resonance Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant

NCT01305200
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Mucositis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
supersaturated calcium phosphate rinse, placebo, questionnaire administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 21 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
31
States / cities
Arcadia, California • Duarte, California • Oakland, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 31, 2026, 2:02 PM EDT
Withdrawn Phase 2 Interventional

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

NCT04044209
View directory record Official record
Conditions
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Interventions
AG-120, Nivolumab
Drug
Lead sponsor
Yale University
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 31, 2026, 2:02 PM EDT
Terminated Phase 1 Interventional

Use of Adipose Derived Regenerative Cells in Bilateral Femoral Head Osteonecrosis

NCT03269409
View directory record Official record
Conditions
Osteonecrosis
Interventions
Lactated Ringers, The Celution 800/GP System (Cytori Therapeutics), Adipose Derived Regenerative Cells (ADRC)
Other · Device · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
22 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 31, 2026, 2:02 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Bone Graft Particle Size on Bone Vitality and Volume

NCT04778709
View directory record Official record
Conditions
Bilateral Sinus Pneumatization, Posterior Maxillary Ridge Atrophy Due to Extraction
Interventions
Puros allograft
Device
Lead sponsor
NYU College of Dentistry
Other
Eligibility
25 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 31, 2026, 2:02 PM EDT
Completed No phase listed Observational

Outcomes Data of Bone Marrow Stem Cells to Treat Hip and Knee Osteoarthritis

NCT01601951
View directory record Official record
Conditions
Hip and Knee Osteoarthritis
Interventions
Procedural, Bone Marrow concentrate injection
Other
Lead sponsor
Regenerative Pain Center, Illinois
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Des Plaines, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 31, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Results available

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

NCT01340651
View directory record Official record
Conditions
Myelofibrosis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Winter Park, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 31, 2026, 2:02 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome

NCT01880437
View directory record Official record
Conditions
Myelodysplastic Syndromes, Myelogenous Leukemia, Acute
Interventions
cytarabine, vismodegib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Stanford, California • Ann Arbor, Michigan • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 31, 2026, 2:02 PM EDT
Completed No phase listed Observational

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

NCT00874211
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
assessment of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
3,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
451
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 31, 2026, 2:02 PM EDT
Completed Not applicable Interventional

Bone Marrow Aspirate Concentrate (BMAC) Supplementation for Osteochondral Lesions

NCT02011295
View directory record Official record
Conditions
Osteochondral Lesions of Talus
Interventions
ankle arthroscopy with debridement and microfracture of the OLT, Bone Marrow Aspirate injection
Procedure · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 95 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 31, 2026, 2:02 PM EDT
Withdrawn Phase 1Phase 2 Interventional

High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

NCT05895201
View directory record Official record
Conditions
Bone Marrow Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Interventions
Sitagliptin, Bortezomib, Cyclophosphamide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 31, 2026, 2:02 PM EDT
Completed Not applicable Interventional

Cognitive Behavioural Therapy to Optimize Post-Operative Recovery Trial

NCT04274530
View directory record Official record
Conditions
Pain, Postoperative, Pain, Acute, Pain, Chronic, Fractures, Closed, Fractures, Open
Interventions
Cognitive Behavioural Therapy
Behavioral
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
1,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Largo, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 31, 2026, 2:02 PM EDT
Active, not recruiting Phase 2 Interventional

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

NCT05201066
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Interventions
decitabine, spartalizumab, sabatolimab, azacitidine, venetoclax, INQOVI (oral decitabine)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Portland, Oregon • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Completed No phase listed Observational

Study and Surgical Treatment of Syringomyelia

NCT00011245
View directory record Official record
Conditions
Syringomyelia
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 31, 2026, 2:02 PM EDT
Terminated Not applicable Interventional

Humeral Compression/Distraction Device

NCT02861495
View directory record Official record
Conditions
Humeral Fractures
Interventions
Humeral Compression/Distraction (CD) Nail
Device
Lead sponsor
Florida Orthopaedic Institute
Network
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 31, 2026, 2:02 PM EDT
Terminated Phase 3 Interventional Results available

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

NCT04308395
View directory record Official record
Conditions
Basal Cell Nevus Syndrome
Interventions
Patidegib Topical Gel, 2%
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Fremont, California • Newport Beach, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 31, 2026, 2:02 PM EDT
Completed No phase listed Observational

Minimally Invasive Dental Occlusion Ties

NCT04985461
View directory record Official record
Conditions
Jaw Fractures, Jaw; Fracture, Upper Jaw, Mandibular Fractures, Maxilla Fracture, Jaw Fixation
Interventions
dental occlusion ties maxillo-mandibular fixation
Device
Lead sponsor
Altru Health System
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 31, 2026, 2:02 PM EDT
Recruiting Not applicable Interventional

Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease

NCT06910969
View directory record Official record
Conditions
Bone Marrow Transplant Complications, Graft-versus-Host Disease
Interventions
HORIZONS Intervention, Minimally enhanced usual care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Miami, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 31, 2026, 2:02 PM EDT
Terminated Phase 1 Interventional

A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS

NCT01085656
View directory record Official record
Conditions
Leukemia, Myelogenous, Acute, Myelodysplastic Syndromes
Interventions
OXi4503
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 31, 2026, 2:02 PM EDT